Molecular targeted agents--where we are and where we are going
Author:
Open Access
- 5 May 2013
- journal article
- Published by Editorial Office of Chinese Journal of Cancer in Chinese Journal of Cancer
- Vol. 32 (5) , 225-232
Abstract
A total of 23 new cancer medicines or indication expansions were approved by the U. S. Food and Drug Administration in 2012. Among these, 12 are new molecular entities (NMEs)--new chemical or biological drugs approved for the first time for oncologic use--and 10 of these NMEs are molecular targeted agents. Among the 10 targeted agents, 4 are anti-angiogenesis agents and 2 are Bcr-Abl pathway inhibitors, targeting well established targets validated by previously approved agents such as bevacizumab (Avastin) or imatinib (Gleevec). Despite this progress, several questions remain: Do these newly approved agents provide sufficient treatment options to manage the broad spectrum of cancers we deal with in the clinic? Where will the next wave of new cancer drugs come from? Where should R&D efforts be invested to continue improve cancer treatment and management, especially for tumor types uniquely prevalent in China? This editorial and the review articles in this special issue of Chinese Journal of Cancer provide an in depth review of the progress and challenges in developing targeted cancer therapies, as well as an outlook of new research areas where near term breakthroughs are expected to overcome some of these challenges.Keywords
This publication has 14 references indexed in Scilit:
- Impact of genetic alterations on mTOR-targeted cancer therapyChinese Journal of Cancer, 2013
- Targeting the PI3K-AKT-mTOR signaling network in cancerChinese Journal of Cancer, 2013
- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell CarcinomaNew England Journal of Medicine, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerNew England Journal of Medicine, 2012
- PARP inhibitors: its role in treatment of cancerChinese Journal of Cancer, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitationsChinese Journal of Cancer, 2011